Novavax COVID-19 vaccine 90.4% effective in clinical trial, company says
June 14 2021, 08:00
Novavax announced on Monday that its COVID-19 vaccine was found to be over 90% effective overall, and offered 100% protection against moderate and severe disease in a Phase 3 clinical trial.
Novavax announced on Monday that its COVID-19 vaccine was found to be over 90% effective overall, and offered 100% protection against moderate and severe disease in a Phase 3 clinical trial.
Source:
FOX News